drugset / Trial / NCT03120520

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

NCT03120520

Phase 2 Completed 124 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a study of efficacy and safety of Plecanatide in pediatric subjects aged 12 to \< 18 years diagnosed with Chronic Idiopathic Constipation.

Timeline

Start
2017-01
Primary completion
2018-09-07
Completion
2018-09-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Plecanatide Peptide 0.5 mg Oral
Subject Plecanatide Peptide 1 mg Oral
Subject Plecanatide Peptide 1.5 mg Oral

Indications